Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma

Han Ching Tang, Kuo Hsuan Chung

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Objective: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia. There are some case reports about this side effect of quetiapine, but possible risk factors are seldom discussed and identified. A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here. Case Report: A 62-year-old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60. She developed leucopenia after being treated with quetiapine. After quetiapine was discontinued, her white blood cell count returned to normal. Conclusions: Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors. Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.

Original languageEnglish
Pages (from-to)255-261
Number of pages7
JournalInternational Journal of Psychiatry in Medicine
Issue number3
Publication statusPublished - Jan 1 2014


  • bipolar disorder
  • blood dyscrasias
  • hepatic dysfunction
  • neutropenia
  • quetiapine

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this